TY - JOUR
T1 - Psychological and behavioural effects of interferons
AU - Bonaccorso, Stefania
AU - Meltzer, Herbert
AU - Maes, Michael
PY - 2000
Y1 - 2000
N2 - Immunotherapy with interferons may induce neuropsychiatric symptoms and disorders. Interferon-α-based immunotherapy is used to treat patients with chronic hepatitis C and metastatic renal cell carcinoma. Immunotherapy with interferon-α induces symptoms such as slowness, severe fatigue, hypersomnia, lethargy, depressed mood, mnemonic troubles, irritability, short temper, emotional lability, social withdrawal, lack of concentration and full blown major depression in a considerable number of patients treated. The exact mechanism whereby interferon-α induces depression has remained elusive. However, there is now some evidence that interferon-α-based immunotherapy induces the cytokine network, decreases the serotonergic turnover in the brain, and induces the catabolism of tryptophan. There is evidence that interferon-α immunotherapy-induced depression is related to an increased catabolism of tryptophan into kynurenine. (C) 2000 Lippincott Williams and Wilkins.
AB - Immunotherapy with interferons may induce neuropsychiatric symptoms and disorders. Interferon-α-based immunotherapy is used to treat patients with chronic hepatitis C and metastatic renal cell carcinoma. Immunotherapy with interferon-α induces symptoms such as slowness, severe fatigue, hypersomnia, lethargy, depressed mood, mnemonic troubles, irritability, short temper, emotional lability, social withdrawal, lack of concentration and full blown major depression in a considerable number of patients treated. The exact mechanism whereby interferon-α induces depression has remained elusive. However, there is now some evidence that interferon-α-based immunotherapy induces the cytokine network, decreases the serotonergic turnover in the brain, and induces the catabolism of tryptophan. There is evidence that interferon-α immunotherapy-induced depression is related to an increased catabolism of tryptophan into kynurenine. (C) 2000 Lippincott Williams and Wilkins.
UR - http://www.scopus.com/inward/record.url?scp=0033769134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033769134&partnerID=8YFLogxK
U2 - 10.1097/00001504-200011000-00034
DO - 10.1097/00001504-200011000-00034
M3 - Review article
AN - SCOPUS:0033769134
SN - 0951-7367
VL - 13
SP - 673
EP - 677
JO - Current opinion in psychiatry
JF - Current opinion in psychiatry
IS - 6
ER -